Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Cardoso, F ^a   Castiglione, M ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PACLITAXEL; PERTUZUMAB; SUNITINIB; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; INCIDENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; THORAX RADIOGRAPHY; TREATMENT RESPONSE;

BREAST NEOPLASMS; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549111590     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp115     Document Type: Article

References (11)

1. ESO-MBC Task Force. Metastatic breast cancer. Recommendations proposal from the European School of Oncology (ESO)-MBC Task Force. Breast 2007; 16: 9-10.
2. Kataja V, Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2): Ii11-ii13.
3. Network NCC. 2008. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2. In Edition 2008.
4. Colozza M, de Azambuja E, Personeni N et al. Achievements in systemic therapies in the pre-genomic era in metastatic breast cancer. Oncologist 2007; 12: 253-270.
5. Chan S, Friedrichs K, Noel D et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17: 2341-2354.
6. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
7. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment: Final results of a global phase III study. J Clin Oncol 2008; 26: 3950-3957.
8. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19: 2722-2730.
9. Miller K, Wang M, Gralow J et al. Paclitaxel pus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
10. Gennari A, Amadori D, De Lena M et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol 2006; 24: 3912-3918.
11. Ghersi D, Wilcken N, Simes J et al. Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2003; 3: CD003366.